Histone Methylation Related Therapeutic Challenge in Cardiovascular Diseases

Abstract

The epidemic of cardiovascular diseases (CVDs) is predicted to spread rapidly in advanced countries accompanied by the high prevalence of risk factors. In terms of pathogenesis, the pathophysiology of CVDs is featured by multiple disorders, including vascular inflammation accompanied by simultaneously perturbed pathways, such as cell death and acute/chronic inflammatory reactions. Epigenetic alteration is involved in the regulation of genome stabilization and cellular homeostasis. The association between CVD progression and histone modifications is widely known. Among the histone modifications, histone methylation is a reversible process involved in the development and homeostasis of the cardiovascular system. Abnormal methylation can promote CVD progression. This review discusses histone methylation and the enzymes involved in the cardiovascular system and determine the effects of histone methyltransferases and demethylases on the pathogenesis of CVDs. We will further demonstrate key proteins mediated by histone methylation in blood vessels and review histone methylation-mediated cardiomyocytes and cellular functions and pathways in CVDs. Finally, we will summarize the role of inhibitors of histone methylation and demethylation in CVDs and analyze their therapeutic potential, based on previous studies.

Scopoletin inhibits PDGF-BB-induced proliferation and migration of airway smooth muscle cells by regulating NF-κκB signaling pathway

“…Inhibition of NF-κB has important clinical significance in the treatment of asthma. 27,29 In addition, multiple drugs treat or improve asthma through this signaling pathway. For example, Korean Red ginseng affected the ovalbumin (OVA)-induced asthma by modulating the NF-κB pathway.…”

Epigenetics and Beyond: Targeting Histone Methylation to Treat Type 2 Diabetes Mellitus

“…The methylation on the lysine residues can be mono-(me), di-(me2), or tri-(me3) on the ε-amino group, whereas for arginine, it can be mono-(me) or di-(me2s) symmetrically or asymmetrically (me2a) ( Kim et al, 2019 ). Histone methylation can be added by histone methyltransferase (HMTs), catalyzing the transfer of a methyl group from S-adenosylmethionine to their targeted residues ( Yang et al, 2021 ). Typically, HMTs are composed of three families: the SET-domain containing enzymes, Dot1-like proteins, and arginine N-methyltransferase enzymes (PRMTs, Figure 1 ; Table 1 ) ( Michalak and Visvader, 2016 ).…”

Epigenetic Regulation in Pathology of Atherosclerosis: A Novel Perspective

“…Studies suggested that epigenetic regulation exerts a pivotal role in many diseases such as cancers and CVDs ( Liu et al, 2021 ; Yang et al, 2021 ). Distinct from genetic alteration, epigenetic modification is reversible, and the inhibitor of epigenetic alteration provides a novel insight into searching pharmaceutical therapeutic targets ( Pons et al, 2009 ).…”